Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock
ATLANTA, GA—For patients with acute MI complicated by cardiogenic shock (AMICS), the routine use of mechanical circulatory support (MCS) with the Impella CP (Abiomed) microaxial flow pump appears to achieve lower mortality at 180 days compared with standard care, according to long-awaited data from the randomized DanGer Shock trial. Investigators also saw a higher rate of safety events with the Impella device, said Jacob Eifer Møller, MD, PhD, DMSc (Copenhagen University Hospital Rigshospitalet, Denmark),